{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:52:02Z","timestamp":1767135122667,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd011088","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T00:00:00Z","timestamp":1513296000000}}],"reference-count":101,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011088.pub2","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T12:10:05Z","timestamp":1515499805000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism"],"prefix":"10.1002","volume":"2017","author":[{"given":"Lindsay","family":"Robertson","sequence":"first","affiliation":[{"name":"Freeman Hospital; Department of Vascular Surgery; Newcastle upon Tyne Hospitals NHS Foundation Trust High Heaton Newcastle upon Tyne UK NE7 7DN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Ern","family":"Yeoh","sequence":"additional","affiliation":[{"name":"The University of Edinburgh; College of Medicine and Veterinary Medicine; Edinburgh UK EH16 4TJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Ramli","sequence":"additional","affiliation":[{"name":"Freeman Hospital; Department of Vascular Surgery; Newcastle upon Tyne Hospitals NHS Foundation Trust High Heaton Newcastle upon Tyne UK NE7 7DN"},{"name":"University of Malaya; Kuala Lumpur Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"10.1002\/14651858.CD011088.pub2-BIB0001|cit1","unstructured":"ACTRN12605000004662 A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism (ASPIRE) www.anzctr.org.au\/trial_view.aspx?ID=17."},{"key":"10.1002\/14651858.CD011088.pub2-BIB0002|cit2","unstructured":"ACTRN12611000684921 A prospective combined analysis of the ASPIRE and WARFASA: multi-centre, randomised, double-blind, placebo-controlled clinical trials examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism www.anzctr.org.au\/trial_view.aspx?ID=343155."},{"key":"10.1002\/14651858.CD011088.pub2-BIB0003|cit3","unstructured":"Anon Aspirin to prevent recurrent venous thromboembolism (ASPIRE) NHMRC Clinical Trials Centre 2008"},{"issue":"23","key":"10.1002\/14651858.CD011088.pub2-BIB0004|cit4","first-page":"2777","article-title":"Aspirin for the prevention of recurrent venous thromboembolism after a first unprovoked event: results of the ASPIRE randomized controlled trial","volume":"126","author":"Brighton","year":"2012","journal-title":"Circulation"},{"issue":"21","key":"10.1002\/14651858.CD011088.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10.1002\/14651858.CD011088.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"Simes","year":"2014","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0007|cit7","unstructured":"NCT02064439 Reduced-dosed rivaroxaban in the long-term prevention of recurrent symptomatic VTE (Venous Thromboembolism) (EinsteinChoice) clinicaltrials.gov\/ct2\/show\/NCT02064439."},{"key":"10.1002\/14651858.CD011088.pub2-BIB0008|cit8","first-page":"0340-6245 (Elec","article-title":"Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study","volume":"114","author":"Weitz","year":"2015","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011088.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0761-8425(08)74358-4","article-title":"Prolongation of anti vitamin K treatment for 18 months versus placebo after 6 months treatment of a first episode of idiopathic pulmonary embolism: a multicentre, randomised double blind trial. The PADIS-PE Trial. [French]","volume":"25","author":"Couturaud","year":"2008","journal-title":"Revue des Maladies Respiratoires"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.2015.7046","article-title":"Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial","volume":"314","author":"Couturaud","year":"2015","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0012|cit12","unstructured":"Couturaud F Sanchez O Presles E Salaun PY Pernod G Mismetti P Risk factors of recurrent venous thromboembolism in patients with a first episode of unprovoked pulmonary embolism: results from the PADIS PE multicenter, double-blind, randomized trial Journal of Thrombosis and Haemostasis 2015 151 2"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0013|cit13","unstructured":"NCT00740883 Extended duration of oral anticoagulant therapy after a first episode of idiopathic pulmonary embolism: a randomized controlled trial. \"PADIS-PE\" study clinicaltrials.gov\/ct2\/show\/NCT00740883?term=NCt00740883&rank=1."},{"issue":"21","key":"10.1002\/14651858.CD011088.pub2-BIB0015|cit14","doi-asserted-by":"crossref","first-page":"A543","DOI":"10.1182\/blood.V118.21.543.543","article-title":"Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. The WARFASA study","volume":"118","author":"Becattini","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD011088.pub2-BIB0014|cit15","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0016|cit16","unstructured":"NCT00222677 Aspirin for the prevention of recurrent venous thromboembolism clinicaltrials.gov\/ct2\/show\/NCT00222677."},{"issue":"3","key":"10.1002\/14651858.CD011088.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","article-title":"Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators","volume":"345","author":"Agnelli","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011088.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-139-1-200307010-00008","article-title":"Extended oral anticoagulant therapy after a first episode of pulmonary embolism","volume":"139","author":"Agnelli","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011088.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.thromres.2004.12.012","article-title":"Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment","volume":"116","author":"Santamaria","year":"2005","journal-title":"Thrombosis Research"},{"issue":"8","key":"10.1002\/14651858.CD011088.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1182\/blood.V122.21.3638.3638","article-title":"Apixaban reduces hospitalization in patients with venous thromboembolism: an analysis of the Amplify-EXT trial","volume":"122","author":"Liu","year":"2013","journal-title":"Blood"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1160\/TH15-07-0606","article-title":"Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism: an analysis of the AMPLIFY-EXT trial","volume":"115","author":"Liu","year":"2016","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0023|cit23","unstructured":"NCT00633893 Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism clinicaltrials.gov\/ct2\/show\/NCT00633893."},{"key":"10.1002\/14651858.CD011088.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.thromres.2016.06.001","article-title":"Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: rationale and design of the Highlow study, a randomised trial of two doses","volume":"144","author":"Bleker","year":"2016","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Buller HR Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension Study Blood 2010","DOI":"10.1182\/blood.V116.21.187.187"},{"issue":"5","key":"10.1002\/14651858.CD011088.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.thromres.2014.02.006","article-title":"Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism","volume":"133","author":"Coleman","year":"2014","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0027|cit27","unstructured":"NCT00439725 Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension Study https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00439725."},{"issue":"26","key":"10.1002\/14651858.CD011088.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"The EINSTEIN Investigators","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011088.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-9560-12-26","article-title":"Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy","volume":"12","author":"Wells","year":"2014","journal-title":"Thrombosis Journal"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0030|cit30","unstructured":"Wells PS Prins MH Levitan B Yuan Z Katz EG Beyer-Westendorf J Long-term anticoagulation with rivaroxaban for the prevention of recurrent deep venous thrombosis and pulmonary embolism: a benefit-risk analysis on the EINSTEIN EXTENSION trial Journal of Thrombosis and Haemostasis 2015 194"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3111\/13696998.2014.946993","article-title":"Length of stay and economic consequences with rivaroxaban vs enoxaparin\/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program","volume":"17","author":"Bookhart","year":"2014","journal-title":"Journal of Medical Economics"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Buller","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011088.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/acem.12615","article-title":"Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study","volume":"22","author":"Fermann","year":"2015","journal-title":"Academic Emergency Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011088.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.thromres.2014.05.013","article-title":"Treatment of patients with acute deep vein thrombosis and\/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations","volume":"134","author":"Prandoni","year":"2014","journal-title":"Thrombosis Research"},{"issue":"2","key":"10.1002\/14651858.CD011088.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.thromres.2014.11.008","article-title":"Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial","volume":"135","author":"Prins","year":"2015","journal-title":"Thrombosis Research"},{"issue":"5","key":"10.1002\/14651858.CD011088.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1185\/03007995.2013.879439","article-title":"Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism","volume":"30","author":"Bellen","year":"2014","journal-title":"Current Medical Research and Opinion"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011088.pub2-BIB0037|cit37","first-page":"694","article-title":"Rivaroxaban for the treatment of symptomatic deep vein thrombosis and\/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies","volume":"11","author":"Wang","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD011088.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-9560-12-26","article-title":"Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy","volume":"12","author":"Wells","year":"2014","journal-title":"Thrombosis Journal"},{"issue":"5","key":"10.1002\/14651858.CD011088.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00277-008-0626-1","article-title":"6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII","volume":"88","author":"Eischer","year":"2009","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ahj.2016.12.004","article-title":"The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended-Duration Betrixaban (APEX) trial","volume":"185","author":"Gibson","year":"2017","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0047|cit41","unstructured":"Kearon C Two years of warfarin versus placebo following three months of anticoagulation for a first episode of idiopathic venous thromboembolism (VTE) Thrombosis and Haemostasis 1997 767-Abstract No HI-3"},{"issue":"12","key":"10.1002\/14651858.CD011088.pub2-BIB0041|cit42","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199903253401201","article-title":"A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism","volume":"340","author":"Kearon","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0042|cit43","unstructured":"Kearon C Ginsberg JS Anderson DR Kovacs M Wells P Julian J Four weeks versus 12 weeks of anticoagulation for a first episode of venous thromboembolism (VTE) provoked by a transient risk factor: a randomized double-blind trial Blood 2001 Abstract 1879"},{"issue":"5","key":"10.1002\/14651858.CD011088.pub2-BIB0043|cit44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1538-7836.2004.00698.x","article-title":"Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor","volume":"2","author":"Kearon","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"7","key":"10.1002\/14651858.CD011088.pub2-BIB0044|cit45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","article-title":"Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism","volume":"349","author":"Kearon","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0045|cit46","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1056\/NEJMoa035422","article-title":"Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism","volume":"349","author":"Kearon","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011088.pub2-BIB0046|cit47","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1182\/blood-2008-06-163279","article-title":"Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial","volume":"112","author":"Kearon","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD011088.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1253\/circj.CJ-15-0195","article-title":"Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study)","volume":"79","author":"Nakamura","year":"2015","journal-title":"Circulation Journal"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Ridker P Goldhaber S Glynn R Long-term, low-intensity warfarin for the prevention of recurrent venous thromboembolism: the PREVENT trial Journal of Thrombosis and Haemostasis 2003 Abstract OC001","DOI":"10.1016\/S1062-1458(03)00259-9"},{"issue":"1","key":"10.1002\/14651858.CD011088.pub2-BIB0052|cit50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/1358836X9800300114","article-title":"Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial","volume":"3","author":"Ridker","year":"1998","journal-title":"Vascular Medicine"},{"issue":"15","key":"10.1002\/14651858.CD011088.pub2-BIB0050|cit51","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10.1002\/14651858.CD011088.pub2-BIB0051|cit52","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1056\/NEJM200311273492216","article-title":"Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism [comment]","volume":"349","author":"Ridker","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0053|cit53","unstructured":"Schulman S Eriksson H Goldhaber S Kakkar AK Kearon C Kvamme AM Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism Journal of Thrombosis and Haemostasis 2011 22"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0054|cit54","first-page":"225","article-title":"Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II","volume":"11","author":"Schulman","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0055|cit55","unstructured":"Schulman S Eriksson H Kakkar A Kearon C Schellong S Feuring M Net clinical benefit of dabigatran versus warfarin in prevention of recurrent venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II Journal of Thrombosis and Haemostasis 2015 644 5"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"A205","DOI":"10.1182\/blood.V118.21.205.205","article-title":"A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II)","volume":"118","author":"Schulman","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1002\/14651858.CD011088.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"A21","DOI":"10.1182\/blood.V120.21.21.21","article-title":"Benefit of extended maintenance therapy for venous thromboembolism with dabigatran etexilate is maintained over 1 year of post-treatment follow-up","volume":"120","author":"Schulman","year":"2012","journal-title":"Blood"},{"issue":"9 Suppl 2","key":"10.1002\/14651858.CD011088.pub2-BIB0059|cit59","first-page":"22","article-title":"Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism","volume":"22","author":"Schulman","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"8","key":"10.1002\/14651858.CD011088.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011088.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.115.016930","article-title":"Sulodexide for the prevention of recurrent venous thromboembolism: the SURVET study: a multicenter, randomized, double-blind, placebo controlled trial","volume":"20","author":"Andreozzi","year":"2015","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0063|cit63","unstructured":"EUDRACT_NUMBER:2009-016923-77 Multicentre, randomised, double blind, placebo controlled study on long-term treatment with sulodexide for prevention of recurrent DVT in patients with venous thromboembolism - SURVET apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2009-016923-77-SK."},{"issue":"11","key":"10.1002\/14651858.CD011088.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa067703","article-title":"Extended prophylaxis of venous thromboembolism with idraparinux","volume":"357","author":"The Van Gogh Investigators","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011088.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1024\/0301-1526.38.3.238","article-title":"The development of persistent thrombotic masses in patients with deep venous thrombosis randomized to long-term anticoagulation treatment","volume":"38","author":"Vitovec","year":"2009","journal-title":"Vasa"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0066|cit66","unstructured":"NCT00740493 Prolonged anticoagulation after a first episode of idiopathic proximal deep vein thrombosis (PADIS TVP) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00740493."},{"issue":"8","key":"10.1002\/14651858.CD011088.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"7454","key":"10.1002\/14651858.CD011088.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"9383","key":"10.1002\/14651858.CD011088.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(03)14111-6","article-title":"Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study","volume":"362","author":"Baglin","year":"2003","journal-title":"Lancet"},{"issue":"26","key":"10.1002\/14651858.CD011088.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD011088.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"d3036","DOI":"10.1136\/bmj.d3036","article-title":"Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials","volume":"342","author":"Boutitie","year":"2011","journal-title":"BMJ"},{"issue":"21","key":"10.1002\/14651858.CD011088.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011088.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-152-9-201005040-00008","article-title":"Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism","volume":"152","author":"Carrier","year":"2010","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011088.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"11","key":"10.1002\/14651858.CD011088.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"766","DOI":"10.7326\/0003-4819-147-11-200712040-00007","article-title":"The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism","volume":"147","author":"Douketis","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"14","key":"10.1002\/14651858.CD011088.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.109.925214","article-title":"Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model","volume":"121","author":"Eichinger","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0078|cit78","unstructured":"McMaster University (developed by Evidence Prime) GRADEproGDT 2015"},{"issue":"6","key":"10.1002\/14651858.CD011088.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinte.160.6.761","article-title":"Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study","volume":"160","author":"Heit","year":"2000","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0080|cit80","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Versions 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"15","key":"10.1002\/14651858.CD011088.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011088.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"issue":"9465","key":"10.1002\/14651858.CD011088.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(05)71880-8","article-title":"Deep vein thrombosis","volume":"365","author":"Kyrle","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0140-6736(10)60962-2","article-title":"Risk assessment for recurrent venous thrombosis","volume":"376","author":"Kyrle","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0085|cit85","first-page":"1","article-title":"Long-term consequences of deep vein thrombosis","volume":"28 Suppl 3","author":"Leizorovicz","year":"1998","journal-title":"Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD011088.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1055\/s-0037-1613230","article-title":"Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism","volume":"88","author":"Murin","year":"2002","journal-title":"Thrombosis and Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD011088.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thromboembolism: a population-based study","volume":"5","author":"Naess","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD011088.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1055\/s-0037-1613887","article-title":"Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale","volume":"83","author":"Oger","year":"2000","journal-title":"Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD011088.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-125-1-199607010-00001","article-title":"The long-term clinical course of acute deep venous thrombosis","volume":"125","author":"Prandoni","year":"1996","journal-title":"Annals of Internal Medicine"},{"issue":"8824","key":"10.1002\/14651858.CD011088.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0140-6736(92)93285-U","article-title":"Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism","volume":"340","author":"Research Committee of the British Thoracic Society","year":"1992","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0091|cit91","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"5","key":"10.1002\/14651858.CD011088.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1503\/cmaj.080493","article-title":"Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy","volume":"179","author":"Rodger","year":"2008","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"692-4","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"24","key":"10.1002\/14651858.CD011088.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011088.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011088.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"211","DOI":"10.7326\/0003-4819-146-3-200702060-00150","article-title":"Management of venous thromboembolism: a systematic review for a practice guideline","volume":"146","author":"Segal","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011088.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1525-1497.2006.00458.x","article-title":"The Worcester Venous Thromboembolism Study: a population-based study of the clinical epidemiology of venous thromboembolism","volume":"21","author":"Spencer","year":"2006","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0098|cit98","article-title":"Chapter 10: Addressing reporting biases","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sterne","year":"2011. Available from www.handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD011088.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1538-7836.2012.04735.x","article-title":"Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)","volume":"10","author":"Tosetto","year":"2012","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011088.pub2-BIB0100|cit100","article-title":"Anticoagulant and fibrinolytic drugs","volume-title":"Hematology Basic Principles and Practice","author":"Weitz","year":"2005"},{"issue":"4","key":"10.1002\/14651858.CD011088.pub2-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011088","article-title":"Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism","author":"Blickstein","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011088.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T01:04:30Z","timestamp":1692407070000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011088.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,12,15]]},"references-count":101,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011088.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,15]]}}}